Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.
Henrik Sillesen, MD, DMSc
Department of Vascular Surgery
Gentofte University Hospital
DK–2900 Hellerup (Denmark)
Tel. +45 3977 3402, Fax +45 3977 7674, E-Mail firstname.lastname@example.org
Received: February 4, 2003
Accepted: February 14, 2003
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 3, Number of References : 31
Cerebrovascular Diseases (Official Journal of the European Stroke Council)
Vol. 16, No. 4, Year 2003 (Cover Date: Released September 2003)
Journal Editor: J. Bogousslavsky, Lausanne; M.G. Hennerici, Mannheim
ISSN: 1015–9770 (print), 1421–9786 (Online)
For additional information: http://www.karger.com/journals/ced
Article / Publication Details
Published online: 9/19/2003
Issue release date: September 2003
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: http://www.karger.com/CED
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.